comparemela.com

Latest Breaking News On - ஹம்போல்ட் அடித்தளம் - Page 4 : comparemela.com

Remembering Tania Douglas: a brilliant biomedical engineer, academic and friend

Tributes from friends, colleagues, collaborators and students have poured in for South African academic Professor Tania Samantha Douglas, an internationally recognised scholar, biomedical engineer and innovator. She passed away on 20 March 2021. She was admired by many and consulted broadly for her unique insights, in-depth understanding of South Africa’s higher education environment, and open-mindedness. Always vibrant, she was able to fully engage with issues in an unbiased manner – sharing her well-considered thoughts in a friendly and practical way. Tania obtained the second highest grade in the country in her final school exams in 1987. She went on to read for a BScEng in Electrical and Electronic Engineering at the University of Cape Town (UCT). This was followed by an MS in Biomedical Engineering at Vanderbilt University in Nashville, Tennessee. Then came a PhD in Bioengineering from the University of Strathclyde in Glasgow, and a postdoctoral fellowship in image proces

Novel Materials: Sound Waves Traveling Backwards

RepliCel Life Sciences, Inc : RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor

RepliCel Life Sciences, Inc.: RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor VANCOUVER, BC / ACCESSWIRE / May 17, 2021 / RepliCel Life Sciences Inc. (OTCPINK:REPCF) (TSXV:RP) (FRA:P6P2) ( RepliCel or the Company ), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Professor Akimichi Morita, one of Japan s leading dermatology research clinicians, has agreed to be RepliCel s clinical advisor for the development and commercialization of its skin rejuvenation product (RCS-01) in Japan. The Company, working with industry leaders, CJ Partners, and clinical research organization, Accerise, is currently preparing to support the next-phase clinical research study of its skin rejuvenation cell therapy, RCS-01, in Japan under the Act for Safety of Regenerative Medicine (ASRM) that, upon successfully meeting its endpoints, could lead to a commercial launch of the product in Japan.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.